{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:09:13Z","timestamp":1770822553147,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1053\/j.seminhematol.2010.11.005","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T05:43:28Z","timestamp":1294811008000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of Flow Cytometry of Peripheral Blood and Bone Marrow Aspirates in Early Myeloma"],"prefix":"10.1053","volume":"48","author":[{"given":"Constance M.","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.11.005_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78B","author":"Paiva","year":"2010","journal-title":"Cytometry"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2141.2006.06068.x","article-title":"Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration","volume":"133","author":"Nadav","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2009.009100","article-title":"Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients","volume":"94","author":"Paiva","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib5","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/cyto.b.20365","article-title":"2006 Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications","volume":"72B","author":"Davis","year":"2007","journal-title":"Cytometry"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib7","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib8","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.1999.01685.x","article-title":"High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma","volume":"107","author":"Almeida","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1309\/3G1XDX0DVHBNVKB4","article-title":"Immunophenotypic profile of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia","volume":"124","author":"Konoplev","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10428199809057596","article-title":"Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia","volume":"31","author":"Witzig","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0609.2006.00661.x","article-title":"Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma","volume":"77","author":"Sahara","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib14","first-page":"489","article-title":"CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q","volume":"90","author":"Liebisch","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib15","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells","volume":"91","author":"Bataille","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib16","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cyto.b.20523","article-title":"Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma","volume":"78B","author":"Johnsen","year":"2010","journal-title":"Cytometry"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib19","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib20","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood-2009-05-221689","article-title":"The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients","volume":"114","author":"Paiva","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78B","author":"Paiva","year":"2010","journal-title":"Cytometry"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1309\/5EL22BH45PHUPM8P","article-title":"Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma","volume":"127","author":"Seegmiller","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","article-title":"CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications","volume":"25","author":"Treon","year":"2002","journal-title":"J Immunother"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood-2002-12-3784","article-title":"Expression of CD52 on plasma cells in plasma cell proliferative disorders","volume":"102","author":"Kumar","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1470-2045(08)70304-8","article-title":"New drugs in multiple myeloma: mechanisms of action and phase I\/II clinical findings","volume":"9","author":"Ocio","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib26","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"Perez-Persona","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/07853890903111000","article-title":"Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance","volume":"41","author":"Jerez","year":"2009","journal-title":"Ann Med"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08121.x","article-title":"Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders","volume":"149","author":"Raja","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.leukres.2007.07.016","article-title":"CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis","volume":"32","author":"Bataille","year":"2008","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib31","first-page":"547","article-title":"Patients with CD45 negative multiple myeloma receiving high-dose therapy have it shorter survival than those with CD45 positive multiple myeloma","volume":"89","author":"Moreau","year":"2004","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.bmt.1705857","article-title":"Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)","volume":"40","author":"Hundemer","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2141.1999.01134.x","article-title":"Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression","volume":"104","author":"Rawstron","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib34","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","article-title":"Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma","volume":"117","author":"Sahara","year":"2002","journal-title":"Br J Hematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10428199609054799","article-title":"DNA cell content studies in multiple myeloma","volume":"23","author":"San Miguel","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V85.2.448.448","article-title":"A new staging system for multiple myeloma based on the number of S-phase plasma cells","volume":"85","author":"San Miguel","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/(SICI)1097-0320(19991215)38:6<286::AID-CYTO5>3.0.CO;2-7","article-title":"The bone marrow plasma cell labeling index by flow cytometry","volume":"38","author":"Pope","year":"1999","journal-title":"Cytometry"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0950-3536(05)80257-4","article-title":"Immunophenotype and DNA cell content in multiple myeloma","volume":"8","author":"San Miguel","year":"1995","journal-title":"Baillieres Clin Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","article-title":"Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"114","author":"Kapoor","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib40","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3324\/haematol.2009.018689","article-title":"Circulating human B and plasma cells","volume":"95","author":"Caraux","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib41","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood.V88.1.289.289","article-title":"Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma","volume":"88","author":"Billadeau","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2141.2006.06479.x","article-title":"Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma","volume":"136","author":"Chandesris","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","article-title":"Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage","volume":"97","author":"Rawstron","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib45","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","article-title":"Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system","volume":"107","author":"Dingli","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00432-008-0499-7","article-title":"Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma","volume":"135","author":"Kopp","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib47","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/jcp.49.8.672","article-title":"Assessment of IgH PCR strategies in multiple myeloma","volume":"49","author":"Owen","year":"1996","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1309\/B2P9XEH44CY9LPUK","article-title":"Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow","volume":"125","author":"Zhao","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/10428190701813018","article-title":"Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib50","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib51","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.005_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cyto.b.20517","article-title":"Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology","volume":"78","author":"Cannizzo","year":"2010","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310001083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310001083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:51Z","timestamp":1758522111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310001083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0037196310001083"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Flow Cytometry of Peripheral Blood and Bone Marrow Aspirates in Early Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}